Alzheimer's disease (AD) is a neurodegenerative disease whose various pathophysiological aspects are still being investigated. Recently, it has been hypothesized that AD may be associated with a dysbiosis of microbes in the intestine. In fact, the intestinal flora is able to influence the activity of the brain and cause its dysfunctions.Given the growing interest in this topic, the purpose of this review is to analyze the role of antibiotics in relation to the gut microbiota and AD. In the first part of the review, we briefly review the role of gut microbiota in the brain and the various theories supporting the hypothesis that dysbiosis can be associated with AD pathophysiology. In the second part, we analyze the possible role of antibiotics in these events. Antibiotics are normally used to remove or prevent bacterial colonization in the human body, without targeting specific types of bacteria. As a result, broad-spectrum antibiotics can greatly affect the composition of the gut microbiota, reduce its biodiversity, and delay colonization for a long period after administration. Thus, the action of antibiotics in AD could be wide and even opposite, depending on the type of antibiotic and on the specific role of the microbiome in AD pathogenesis.Alteration of the gut microbiota can induce changes in brain activity, which raise the possibility of therapeutic manipulation of the microbiome in AD and other neurological disorders. This field of research is currently undergoing great development, but therapeutic applications are still far away. Whether a therapeutic manipulation of gut microbiota in AD could be achieved using antibiotics is still not known. The future of antibiotics in AD depends on the research progresses in the role of gut bacteria. We must first understand how and when gut bacteria act to promote AD. Once the role of gut microbiota in AD is well established, one can think to induce modifications of the gut microbiota with the use of pre-, pro-, or antibiotics to produce therapeutic effects.

Memory Clinic Department of Neurology 2nd Faculty of Medicine Charles University and Motol University Hospital Prague Czech Republic

000      

00000naa a2200000 a 4500

001      

bmc19044813

003      

CZ-PrNML

005      

20200115101856.0

007      

ta

008      

200109s2019 xxk f 000 0|eng||

009      

AR

024    7_

$a 10.1186/s12974-019-1494-4 $2 doi

035    __

$a (PubMed)31118068

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a xxk

100    1_

$a Angelucci, Francesco $u Memory Clinic, Department of Neurology, 2nd Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic. francesco.angelucci@lfmotol.cuni.cz.

245    10

$a Antibiotics, gut microbiota, and Alzheimer's disease / $c F. Angelucci, K. Cechova, J. Amlerova, J. Hort,

520    9_

$a Alzheimer's disease (AD) is a neurodegenerative disease whose various pathophysiological aspects are still being investigated. Recently, it has been hypothesized that AD may be associated with a dysbiosis of microbes in the intestine. In fact, the intestinal flora is able to influence the activity of the brain and cause its dysfunctions.Given the growing interest in this topic, the purpose of this review is to analyze the role of antibiotics in relation to the gut microbiota and AD. In the first part of the review, we briefly review the role of gut microbiota in the brain and the various theories supporting the hypothesis that dysbiosis can be associated with AD pathophysiology. In the second part, we analyze the possible role of antibiotics in these events. Antibiotics are normally used to remove or prevent bacterial colonization in the human body, without targeting specific types of bacteria. As a result, broad-spectrum antibiotics can greatly affect the composition of the gut microbiota, reduce its biodiversity, and delay colonization for a long period after administration. Thus, the action of antibiotics in AD could be wide and even opposite, depending on the type of antibiotic and on the specific role of the microbiome in AD pathogenesis.Alteration of the gut microbiota can induce changes in brain activity, which raise the possibility of therapeutic manipulation of the microbiome in AD and other neurological disorders. This field of research is currently undergoing great development, but therapeutic applications are still far away. Whether a therapeutic manipulation of gut microbiota in AD could be achieved using antibiotics is still not known. The future of antibiotics in AD depends on the research progresses in the role of gut bacteria. We must first understand how and when gut bacteria act to promote AD. Once the role of gut microbiota in AD is well established, one can think to induce modifications of the gut microbiota with the use of pre-, pro-, or antibiotics to produce therapeutic effects.

650    _2

$a Alzheimerova nemoc $x chemicky indukované $x farmakoterapie $x mikrobiologie $7 D000544

650    _2

$a zvířata $7 D000818

650    _2

$a antibakteriální látky $x aplikace a dávkování $x škodlivé účinky $7 D000900

650    _2

$a mozek $x účinky léků $x fyziologie $7 D001921

650    _2

$a dysbióza $x chemicky indukované $x mikrobiologie $7 D064806

650    _2

$a střevní mikroflóra $x účinky léků $x fyziologie $7 D000069196

650    _2

$a lidé $7 D006801

650    _2

$a probiotika $x aplikace a dávkování $x škodlivé účinky $7 D019936

655    _2

$a časopisecké články $7 D016428

655    _2

$a přehledy $7 D016454

700    1_

$a Cechova, Katerina $u Memory Clinic, Department of Neurology, 2nd Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic.

700    1_

$a Amlerova, Jana $u Memory Clinic, Department of Neurology, 2nd Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic.

700    1_

$a Hort, Jakub $u Memory Clinic, Department of Neurology, 2nd Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic.

773    0_

$w MED00163330 $t Journal of neuroinflammation $x 1742-2094 $g Roč. 16, č. 1 (2019), s. 108

856    41

$u https://pubmed.ncbi.nlm.nih.gov/31118068 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y a $z 0

990    __

$a 20200109 $b ABA008

991    __

$a 20200115102229 $b ABA008

999    __

$a ok $b bmc $g 1483082 $s 1083486

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2019 $b 16 $c 1 $d 108 $e 20190522 $i 1742-2094 $m Journal of neuroinflammation $n J Neuroinflammation $x MED00163330

GRA    __

$a LF UK Grant No. 699012 $p Ipe 2

LZP    __

$a Pubmed-20200109